Pfizer, Inc. · NYSE:PFE
Pfizer — Cowen and Company 30th Annual Healthcare Conference (March 2010)
17 slides from Pfizer's conference presentation, Mar 9, 2010
Slide 1: Worldwide Biopharmaceutical Businesses
Worldwide Biopharmaceutical Businesses Ian Read Group President March 9, 2010
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2009 Annual Report on Form 10-K and in o
Slide 3: Biopharmaceutical Revenues
Biopharmaceutical Revenues ($ Millions) Fourth Quarter Total Legacy Pfizer FX 2009 2008 Change Operational Operational Impact Growth Growth Primary Care $6,521 $5,930 10% 4% 6% 1% Specialty Care 2,934 1,595 84% 5% 79% 9% Established Products 2,749 1,749 57% 6% 51% 1% Emerging Markets 1,974 1,582 25%
Slide 4: Worldwide Biopharmaceutical Businesses
Worldwide Biopharmaceutical Businesses Continued Business Model innovation to meet our diverse customers needs Invest in development to deliver a differentiated, innovative pipeline Optimize the patent-protected portfolio within Primary Care, Specialty Care and Oncology Accelerate our powerful Emerg
Slide 5: Emerging Markets
Emerging Markets Contribution to WW Pharma Growth Pfizer: Significant Investment Significant Expansion in Emerging Markets in Field Force (Headcount) 2% 11% Canada 2009 G % 6% ROW 2012 (Projected) 26 11,400 10% Rest of Europe 8,461 27% Japan G % Pharmerging 39 11% 4,700 EU5 2,848 32% US / PR Source:
Slide 6: Established Products
Established Products Stabilize Grow the Declining Base Business 2010 - 2011 2012 Performance & Key Strategies Post-LOE pharmaceutical market expected to double in size (2008 – 2012) Established Products continues to deliver strong performance 2009: $7.6B / +4% operational growth Growth of po
Slide 7: Oncology
Oncology Oncology is poised to become largest pharmaceutical segment in 2014 with >$100B in revenues Pfizer is committed to becoming a significant player Investment in a world-class Oncology team Rich pipeline of 31 biologics & small molecules, with Sutent as foundation Phase 3 Oncology Pipe
Slide 8: Olivier Brandicourt, M.D.
Olivier Brandicourt, M.D. President & General Manager Primary Care Business Unit March 9, 2010
Slide 9: Primary Care Strategy
Primary Care Strategy Portfolio of Highly Differentiated Medicines, Technologies & Solutions Primary Care Objective Chronic, Costly Populations Intent to become the Significant Unmet Medical Needs world’s local partner of choice with medicines, + Distinctive Primary Care technologies and solutio
Slide 10: Primary Care: At the Core of Pfizer's Business
Primary Care: At the Core of Pfizer’s Business Primary Care is Where… Patient engagement with #1 in Primary Care healthcare starts Billions of customer Ongoing care is coordinated interactions; helped 55 million and chronic disease patients in 2009 management happens Customer teams that de
Slide 11: Number One Primary Care Company in the World
Number One Primary Care Company in the World Key Growth Cornerstone Brands Opportunities Pain Alzheimer’s Disease Depression/Anxiety CV Respiratory Women’s Health Urology 11 Working Together for a Healthier World
Slide 12: Pipeline Focused on Delivering in High Value Areas
Pipeline Focused on Delivering in High Value Areas Apixaban Aprela Pristiq VMS Tanezumab (CV) (Women’s Health) (Depression) (Pain) Novel MOA, multiple 1st TSEC, providing In line for major postmenopausal women 10 Phase 3 trials indications with a potential new depression, (atrial fibrillation, o
Slide 13: Geno Germano
Geno Germano President & General Manager Specialty Care Business Unit March 9, 2010
Slide 14: Pfizer is the Number One Specialty Care Company in the World
Pfizer is the Number One Specialty Care Company in the World Specialty Care’s Broad In-line Portfolio and Pipeline Have More Than 25 New Compounds or Indications in 11 Disease Areas / / Infectious PAH / PVD Diseases Endocrine Specialty Care BU Ophthalmics Gastro- intestinal Disease Areas Neuroscienc
Slide 15: Pfizer Specialty Care Leads the Industry in Key Therapeutic Areas
Pfizer Specialty Care Leads the Industry in Key Therapeutic Areas The world’s largest specialty medicine ever. We are the fourth-largest company in inflammation with key expertise to bring our JAK inhibitor and broad inflammation pipeline successfully to market, if approved The world’s biggest-s
Slide 16: Pfizer Specialty Care Supports Key Development Initiatives Across Disease Areas
Pfizer Specialty Care Supports Key Development Initiatives Across Disease Areas Internal Development Partnered Development Prevnar13 Tasocitinib / JAK Bapineuzumab Xiaflex (Adult Indication) (Inflammation) (Alzheimer’s) (Dupuytren’s) Novel MOA Inhibiting Disease Modification Significant Unmet Huge P
Slide 17: Working Together for a Healthier World
Working Together for a Healthier World 17 Working Together for a Healthier World
Pfizer — Cowen and Company 30th Annual Healthcare Conference (March 2010) on 6ix